Semaglutide Reduces Cardiovascular Risk in Patients With Heart Failure

A large-scale trial has shown that the medication semaglutide can significantly reduce the risk of major adverse cardiovascular events and heart failure in patients with overweight or obesity and heart failure. The study, conducted in 41 countries, involved 17,604 patients who were randomly assigned to receive semaglutide or a placebo. The results demonstrated that semaglutide improved outcomes in patients with heart failure, with significant reductions in the incidence of clinical events such as major adverse cardiovascular events, heart failure composite end point, cardiovascular death, and all-cause death.

Key Takeaways:

• Semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 10% compared to placebo in patients with overweight or obesity and heart failure.
• The medication also improved outcomes in patients with heart failure, reducing the composite heart failure end point by 11% compared to placebo.
• Semaglutide treatment resulted in improved outcomes in MACE and the composite heart failure end point in both patients with heart failure with reduced ejection fraction and heart failure with preserved ejection fraction.
• The study involved 17,604 patients (age, 45 years and older; body mass index, ≥ 27 kg/m2) who were randomly assigned to receive semaglutide or placebo (8,803 and 8,801 patients, respectively).
• The researchers found that the incidence of clinical events was higher for patients with heart failure, with 24.3% of patients having a history of investigator-defined heart failure at enrollment.
• Several authors disclosed ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.

Statistics:

• 17,604 patients were involved in the study.
• 8,803 patients received semaglutide, while 8,801 received a placebo.
• Semaglutide reduced the risk of MACE by 10% in patients with overweight or obesity and heart failure.
• Semaglutide reduced the composite heart failure end point by 11% in patients with heart failure.
• 24.3% of patients had a history of investigator-defined heart failure at enrollment.

Sources:

• The Lancet, "Semaglutide and cardiovascular outcomes in patients with atherosclerotic cardiovascular disease and overweight or obesity: a randomised, double-blind, multicentre, phase 3 trial".
• Novo Nordisk, manufacturer of semaglutide.
• University College London, Institute of Cardiovascular Sciences.